Hepatocyte Stress Increases Expression of Yes‐Associated Protein and Transcriptional Coactivator With PDZ‐Binding Motif in Hepatocytes to Promote Parenchymal Inflammation and Fibrosis
- 10 September 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 71 (5) , 1813-1830
Abstract
Background and Aims: Activated hepatocytes are hypothesized to be a major source of signals that drive cirrhosis, but the biochemical pathways that convert hepatocytes into such a state are unclear. We examined the role of the Hippo pathway transcriptional coactivators Yes‐associated protein (YAP) and transcriptional coactivator with PDZ‐binding motif (TAZ) in hepatocytes to facilitate cell–cell interactions that stimulate liver inflammation and fibrosis. Approach and Results: Using a variety of genetic, metabolic, and liver injury models in mice, we manipulated Hippo signaling in hepatocytes and examined its effects in nonparenchymal cells to promote liver inflammation and fibrosis. YAP‐expressing hepatocytes rapidly and potently activate the expression of proteins that promote fibrosis (collagen type I alpha 1 chain, tissue inhibitor of metalloproteinase 1, platelet‐derived growth factor c, transforming growth factor β2) and inflammation (tumor necrosis factor, interleukin 1β). They stimulate expansion of myofibroblasts and immune cells, followed by aggressive liver fibrosis. In contrast, hepatocyte‐specific YAP and YAP/TAZ knockouts exhibit limited myofibroblast expansion, less inflammation, and decreased fibrosis after CCl4 injury despite a similar degree of necrosis as controls. We identified cellular communication network factor 1 (CYR61) as a chemokine that is up‐regulated by hepatocytes during liver injury but is expressed at significantly lower levels in mice with hepatocyte‐specific deletion of YAP or TAZ. Gain‐of‐function and loss‐of‐function experiments with CYR61 in vivo point to it being a key chemokine controlling liver fibrosis and inflammation in the context of YAP/TAZ. There is a direct correlation between levels of YAP/TAZ and CYR61 in liver tissues of patients with high‐grade nonalcoholic steatohepatitis. Conclusions: Liver injury in mice and humans increases levels of YAP/TAZ/CYR61 in hepatocytes, thus attracting macrophages to the liver to promote inflammation and fibrosis.Keywords
Funding Information
- National Cancer Institute (R01CA183119)
- National Institute of Diabetes and Digestive and Kidney Diseases (2P30DK034854, K08DK105351, P30DK40561, R01DK031036, R01DK033201, R01DK099559)
- Center for Information Technology (UL1RR025758)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD000850)
This publication has 48 references indexed in Scilit:
- YAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29Nature Cell Biology, 2012
- Yes-associated protein regulates the hepatic response after bile duct ligationHepatology, 2012
- Taxol Resistance in Breast Cancer Cells Is Mediated by the Hippo Pathway Component TAZ and Its Downstream Transcriptional TargetsCyr61andCTGFCancer Research, 2011
- Yap1 Acts Downstream of α-Catenin to Control Epidermal ProliferationCell, 2011
- NF-κB and STAT3 – key players in liver inflammation and cancerCell Research, 2010
- TEAD mediates YAP-dependent gene induction and growth controlGenes & Development, 2008
- TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo PathwayMolecular and Cellular Biology, 2008
- Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth controlGenes & Development, 2007
- Elucidation of a Universal Size-Control Mechanism in Drosophila and MammalsCell, 2007
- Transforming properties of YAP , a candidate oncogene on the chromosome 11q22 ampliconProceedings of the National Academy of Sciences, 2006